Cornelius Mccarthy III Sells 1,140 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Cornelius Mccarthy III sold 1,140 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director directly owned 12,275 shares in the company, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Trading Down 0.6%

Shares of NASDAQ MEDP opened at $578.50 on Friday. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a 50-day moving average of $536.23 and a two-hundred day moving average of $492.35. The company has a market cap of $16.15 billion, a PE ratio of 33.91, a P/E/G ratio of 2.60 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MEDP. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and upped their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $584.18.

Institutional Investors Weigh In On Medpace

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. bought a new position in Medpace during the second quarter worth about $27,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC bought a new stake in shares of Medpace in the 4th quarter valued at about $30,000. Jones Financial Companies Lllp bought a new stake in shares of Medpace in the 2nd quarter valued at about $30,000. Finally, Allied Private Wealth LLC acquired a new stake in shares of Medpace in the 2nd quarter valued at approximately $31,000. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.